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ABSTRACT
Maternal metabolism changes substantially
during pregnancy, which poses numerous
challenges to physicians managing pregnancy
in women with diabetes. Insulin is the agent of
choice for glycemic control in pregnant women
with diabetes, and the insulin analogs are
particularly interesting for use in pregnancy.
These agents may reduce the risk of
hypoglycemia and promote a more
physiological glycemic profile than regular
human insulin in pregnant women with
type 1 (T1D), type 2 (T2D), or gestational
(GDM) diabetes. However, there have been
concerns regarding potential risk for crossing
the placental barrier, mitogenic stimulation,
teratogenicity, and embryotoxicity. Insulin
lispro protamine suspension (ILPS), an
intermediate- to long-acting insulin, has a
stable and predictable pharmacological profile,
and appears to have a favorable time–action
profile and produce desirable basal and
postprandial glycemic control. As the binding
of insulin lispro is unaffected by the protamine
molecule, ILPS is likely to have the same
mitogenic and immunogenic potential as
insulin lispro. Insulin lispro produces similar
outcomes to regular insulin in pregnant women
with T1D, T2D, or GDM, does not cross the
placental barrier, and is considered a useful
treatment option for pregnant women with
diabetes. Clinical data support the usefulness
of ILPS for basal insulin coverage in
non-pregnant patients with T1D or T2D, and
suggest that the optimal regimen, in terms of
balance between efficacy and hypoglycemic
risk, is a once-daily injection, especially in
patients with T2D. Available data concerning
use of ILPS in pregnant women are currently
derived from retrospective analyses that
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involved, in total, [1200 pregnant women.
These analyses suggest that ILPS is at least as
safe and effective as neutral protamine
Hagedorn insulin. Thus, available
experimental and clinical data suggest that
ILPS once daily is a safe and effective option
for the management of diabetes in pregnant
women.
Funding: Eli Lilly and Company.
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INTRODUCTION
The prevalence of diabetes is increasing globally
[1, 2], as are the incidences of pre-existing and
gestational diabetes (GDM) in pregnant women
[3]. Since the prevalence of diabetes (both types
1 and 2) in children and adolescents is also
increasing [4], it is likely that we will continue
to see increases in the incidence of pregnancy
complicated by diabetes.
Women with pre-existing type 1 diabetes
(T1D) or type 2 diabetes (T2D) have increased
risk of several maternal and fetal adverse
outcomes during pregnancy [5–13]. In this
context, increased glucose levels play an
important role in the pathogenesis of
congenital malformations and perinatal
complications, and there is an association
between poor glycemic control in the
periconceptional period and increased risk of
maternal and fetal anomalies [5, 9, 14–16].
It is therefore recommended that glycemic
targets for pregnant women with diabetes be as
close as possible to the normal range [10, 17,
18], taking into account the physiological
decreases in glucose and glycated hemoglobin
(HbA1c) levels that occur during pregnancy in
non-diabetic women [19]. Very good glycemic
control should thus be achieved, while avoiding
hypoglycemic episodes [20] and ensuring that
fetal growth is not compromised [21–23].
This review provides an overview of the
insulins available for treating pregnant women
with diabetes, with an emphasis on insulin
analogs in general and on insulin lispro
protamine suspension (ILPS), an intermediate-
to long-acting insulin, in particular. ILPS could
be utilized for control of hyperglycemia during
pregnancy. This article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
PHYSIOLOGICAL CHANGES
DURING NORMAL AND DIABETIC
PREGNANCY
Briefly, maternal metabolism changes
substantially during pregnancy [24, 25]. These
changes occur to allow the efficient storage of
nutrients during feeding and the rapid use of
stored nutrients, with minimal catabolism of
maternal protein, during fasting [26].
Early gestation is characterized by an
increase in maternal fat stores and small
increases in insulin sensitivity, to provide
stored nutrients to meet the feto-placental and
maternal demands of late gestation and
lactation. Late pregnancy is characterized by
markedly reduced insulin sensitivity and
increased beta-cell responses, which lead to
increases in maternal plasma glucose and free
fatty acid levels, thereby allowing for greater
availability of nutrients for fetal growth [25, 27].
When considering HbA1c monitoring,
comparison of relevant data collected at
Italian Diabetic Care Units from 445
non-diabetic pregnant women between weeks
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15 and 36 of pregnancy and from 384
non-diabetic non-pregnant women showed
that HbA1c reference intervals were lower
during pregnancy (4.0–5.5% versus 4.8–6.2%;
median, 4.8% versus 5.6%, P\0.001) [19].
HbA1c levels were also slightly higher during
weeks 28–36 of pregnancy than during weeks
25–27 (P\0.002) and weeks 15–24 (P\0.001)
[19]. However, HbA1c levels have shown poor
correlation with mean, fasting, premeal, and
postmeal blood glucose values, with the
incidence of macrosomia and, in women with
GDM, with pregnancy outcomes [28]. This
suggests that the metabolic monitoring of
pregnant women with diabetes should include
not only HbA1c levels, but also daily glucose
level monitoring, to capture glycemic peaks and
glucose variability.
In addition to the changes characteristic of
pregnant women without diabetes, women
with GDM have an imbalance between tissue
insulin requirements for glucose regulation and
the ability of pancreatic beta cells to meet those
requirements [24, 25]. These patients also show
hepatic insulin resistance and defects in insulin
signaling [24, 25]. Impaired insulin sensitivity
during early pregnancy is a predictor of GDM,
whereas impaired beta-cell function is only
evident when GDM has developed [29].
As pregnant women with T1D have a
complete absence of endogenous insulin, the
proper balance of accelerated starvation and
facilitated anabolism, which is characteristic of
pregnancy, must be achieved by therapeutic
intervention [26]. This underlies the difficulty
in maintaining glucose levels in the normal
range and managing the resultant large daily
blood glucose excursions that occur in pregnant
women with T1D. These patients are also more
susceptible to developing ketoacidosis if insulin
is not appropriately administered, because
lipolysis and ketogenesis progress without
the compensatory effect of insulin for control
[26]. Importantly, lipid and lipoprotein
abnormalities are observed in pregnant women
with T1D and poor glycemic control (but not in
those with good glycemic control) and in their
newborns with fetal macrosomia [30].
In pregnant women with T2D, pre-existing
insulin resistance is exacerbated by
pregnancy-related decreases in insulin
sensitivity, so most patients who are
diet-treated at the time of conception require
insulin therapy early in pregnancy [26].
INSULINS AVAILABLE FOR USE
IN PREGNANCY
Insulin is the treatment of choice for any type of
diabetes during pregnancy [10, 31]. In this
context, the optimization of insulin therapy is
critical to ensure (near-)normal glycemic
control without the occurrence of
hypoglycemia and with appropriate weight
gain [31]. The physiological changes in glucose
metabolism that occur in pregnant women
increase demand for rapid-acting insulin
postprandially and require that doses of
intermediate- or long-acting insulins be
adjusted throughout each trimester of
pregnancy, to ensure constant and appropriate
basal insulin levels [31].
Insulins available for use during pregnancy
are shown in Table 1. The time–action profiles
of the insulin analogs make these agents
particularly interesting for use in pregnancy.
These insulin preparations will therefore be the
focus of this section.
In general, insulin analogs may reduce the
risk of hypoglycemia and promote a more
physiological glycemic profile than regular
human insulin in pregnant women with T1D,
T2D, or GDM [34]. However, there are a number
of potential concerns associated with the use of
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these agents during pregnancy. These concerns
include: the risk of anti-insulin antibody
development, which allows insulin to cross the
placental barrier [35]; affinity for the insulin-like
growth factor-1 (IGF-1) receptor and the
consequent risk of mitogenic stimulation; and
the potential risk of teratogenicity and
embryotoxicity (see later text).
Rapid-Acting Insulin Analogs
The rapid-acting insulin analogs (RAIAs),
insulin lispro and insulin aspart, reduce
postprandial hyperglycemia more effectively
than regular human insulin and both are
approved for use in pregnancy by the
European Medicines Agency [36, 37]. No
Table 1 Insulins available for use in pregnancy in selected regions
Insulin Comments [32, 33]
Human
Regular insulin No restrictions on use in diabetes during pregnancy;
does not cross the placental barrier
NPH insulin (isophane insulin) No restrictions on use in diabetes during pregnancy;
does not cross the placental barrier
Rapid-acting insulin analogs
Insulin aspart Can be used in pregnancy; data from two clinical trials (total of 349 exposed
pregnancies) do not indicate any adverse effect on pregnancy or feto-neonatal
health compared with human insulin
Insulin glulisine Caution should be exercised when prescribing to pregnant women, and the drug
should only be used if the potential beneﬁt justiﬁes the potential risk to the fetus;
there are no well-controlled clinical studies, and data are limited in pregnant
women (fewer than 300 pregnancy outcomes)
Insulin lispro Can be used in pregnancy; data from a large number of exposed pregnancies do not
indicate any adverse effect on pregnancy or feto-neonatal health
Intermediate- and long-acting insulin analogs
Insulin detemir Can be considered during pregnancy, but any potential beneﬁt must be weighed
against possible increased risk of adverse pregnancy outcomes; results of one clinical
trial suggest possible increased risk of serious adverse maternal outcomes compared
with isophane insulin; post-marketing data from an additional 250 outcomes from
pregnant women exposed to insulin detemir suggest no maternal or feto-neonatal
toxicity
Insulin degludec No clinical experience in pregnant women
Insulin glargine May be considered during pregnancy, if necessary; no clinical data on exposed
pregnancies from controlled clinical studies available; data from pregnant women
(between 300 and 1000 pregnancy outcomes) indicate no adverse effects on
pregnancy, nor malformative or feto-neonatal toxicity
ILPS Limited clinical experience in pregnancy
ILPS insulin lispro protamine suspension, NPH neutral protamine Hagedorn
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clinical trials involving use of insulin glulisine
in pregnant patients have been published [38]
and, for this reason, its use in this population is
not usually advised.
Although data from randomized controlled
trials (RCTs) are limited, experience with insulin
lispro and insulin aspart has generally indicated
that these RAIAs produce similar outcomes to
regular human insulin in pregnant women with
T1D, T2D, or GDM [34, 39–42]. These latter
findings have led to the conclusion that there is
no evidence of an adverse effect of these
insulins on pregnancy or on the health of the
fetus/newborn [34, 36, 37, 41, 43, 44].
Potential Immunogenicity
The immunogenicity of RAIAs has not been well
investigated. However, insulin lispro elicited
similar levels of antibody formation to regular
human insulin in 42 women with GDM [45]
and the potential for antibody formation with
insulin aspart and regular human insulin is
similar in women with T1D or T2D [46]. Insulin
lispro does not cross the placental barrier [45,
47]; no published data concerning the possible
placental transfer of insulin aspart or insulin
glulisine have been identified.
Mitogenic Potential
In vitro findings suggest that the mitogenic
potential of insulin lispro and insulin aspart is
similar to that of human insulin [48, 49], but
that insulin glulisine may differ in this regard,
inducing significantly greater proliferation than
human insulin in IGF-1 receptor-expressing
cells (P\0.05) [49].
Long-Acting Insulin Analogs
The long-acting insulin analogs (LAIAs) have
potential benefits in the management of
pregnancy in women with T1D because of
their ability to mitigate the risk of nocturnal
hypoglycemia and to provide and maintain the
stringent glycemic targets needed in this
population. A number of studies have shown
that insulin glargine and insulin detemir are
safe and promote good glycemic control during
pregnancy [34, 44, 50–52], and both can be
considered for use in pregnant women (Table 1)
[53, 54]. There is currently no clinical
experience with insulin degludec in pregnant
women, although animal studies have not
revealed any embryotoxicity or teratogenicity
differences between insulin degludec and
regular human insulin [55].
A meta-analysis of clinical studies comparing
maternal and fetal outcomes in a total of 702
women with pregestational diabetes or GDM
receiving either insulin glargine (N = 331) or
neutral protamine Hagedorn (NPH) insulin
(isophane insulin; N = 371) found no
significant differences in glycemic control or
safety-related outcomes between the two
insulins during pregnancy [56]. However, there
was considerable heterogeneity among the
eight studies included in the meta-analysis. No
specific malformative or feto-neonatal toxicity
has been observed with insulin glargine [53].
Similarly, post-marketing data indicate no
adverse effects of insulin detemir on pregnancy,
nor any malformative or feto-neonatal toxicity
[54]. In an RCT involving 310 pregnant women
with T1D, treatment with insulin detemir
resulted in lower fasting plasma glucose levels
than, and non-inferior HbA1c to, NPH insulin
in late pregnancy. Rates of hypoglycemia were
similar with the two insulins. However, there
was a non-significantly higher frequency of
serious maternal adverse events with insulin
detemir compared with NPH insulin (40%
versus 31%), although only 8–12% of these
events were considered by the investigators to
be possibly or probably related to
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investigational drugs [57]. Therefore, it was
concluded that there were no concerns
regarding the tolerability of either insulin. A
subsequent analysis of this study comparing
perinatal outcomes has shown that insulin
detemir was as well tolerated as NPH insulin
in terms of fetal and perinatal morbidity and
mortality, and was without any specific safety
concerns [58].
Potential Immunogenicity
We were unable to identify any data relating to
the immunogenicity of LAIAs. However, an
in vitro analysis using human placenta from
uncomplicated pregnancies found that insulin
glargine does not cross the placental barrier,
except at concentrations higher than those that
are likely to be seen clinically [59].
Mitogenic Potential
There are concerns regarding the affinity of
LAIAs for the IGF-1 receptor and the
consequent risk of mitogenic stimulation.
However, the effects of insulin glargine and
insulin detemir are not consistent across
in vitro studies. In one study, both LAIAs had
a lower affinity for the insulin receptor and a
higher affinity for the IGF-1 receptor than
human insulin [49]. In another study, the
affinities of insulin glargine and insulin
detemir for these receptors were
concentration-dependent [48]. Overall,
compared with human insulin, insulin
glargine had similar or greater affinity for both
the insulin and IGF-1 receptors [48, 60],
whereas insulin detemir had similar or lower
affinity for both receptors [48].
Insulin glargine has two main active
metabolites, M1 and M2 [60]. The M1
metabolite is the main compound detected in
plasma after administration and is responsible
for the metabolic activity of insulin glargine in
patients with T1D [61] and T2D [62]. In an
in vitro study, the binding affinity of M1 and
M2 to insulin receptors was similar to that of
the parent compound, but they had lower
affinity than insulin glargine for IGF-1
receptors in cells expressing these receptors
[60]. The affinity of these metabolites for IGF-1
receptors was similar to that of human insulin
in cells expressing these receptors, and their
mitogenicity was similar to that of human
insulin in human osteosarcoma Saos-2 cells
[60].
Although these in vitro findings suggest an
increased mitogenic potential of LAIAs as
compared with human insulin and RAIAs [49],
data are not conclusive, particularly with
respect to insulin glargine, as its main active
metabolite, M1, has low affinity for IGF-1
receptors [60]. Additionally, available clinical
data do not show differences in the rate of
mitogenic changes between patients with
diabetes treated with insulin glargine and
those receiving regular human insulin [44] and
results of the ORIGIN trial (ClinicalTrials.gov
identifier, NCT00069784) do not support
mitogenic potential with insulin glargine [63].
In this latter trial, after a mean of 6.2 years of
follow-up, patients treated with insulin glargine
had a similar risk of cancer and cancer-related
outcomes as patients who received standard
care (not defined) [63].
ILPS
Pharmacology
To regulate glucose metabolism appropriately in
diabetic patients, low, steady basal insulin levels
should ideally be maintained during fasting
periods. LAIAs were developed to achieve this
result, by using simple titration schedules, while
avoiding the wide pharmacological variability
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of traditional long-acting non-analog insulin
preparations.
ILPS, an intermediate- to long-acting
insulin, is a stable formulation of
co-crystalized insulin lispro and protamine
[64] that appears to have a favorable
time–action profile and to produce desirable
basal and postprandial glycemic control in
patients with T1D and T2D [65]. ILPS has
shown pharmacokinetic and
pharmacodynamic properties similar to those
of NPH insulin in healthy volunteers [66].
However, in patients with T1D, time to peak
insulin concentration tended to be shorter (not
significant) with ILPS than NPH insulin [67].
The duration of glucose-lowering activity of
a single dose of ILPS 0.8 U/kg ([23 h) supports
its use once daily and did not differ significantly
from that observed with insulin glargine or
insulin detemir in patients with T2D [68].
However, ILPS had significantly greater
glucose-lowering activity and produced an
earlier maximum pharmacodynamic response
(measured by glucose infusion rate during
euglycemic glucose clamp testing) compared
with both insulins [68]. Similarly, in patients
with T1D, ILPS produced an earlier and larger
maximum pharmacodynamic response than
insulin detemir (also measured by glucose
infusion rate during euglycemic glucose clamp
testing), with a similar duration of action of just
under 24 h (22 versus 23 h, respectively) for
both agents [69].
Interestingly, compared with insulin
glargine given at a single equivalent dose, ILPS
was associated with lower pharmacodynamic
intrasubject variability, more rapid onset of
action, and greater glucose-lowering activity in
patients with T1D [70]. These characteristics
may provide a more predictable response in
these patients [70]. The pharmacological effect
of ILPS in patients with T2D was
dose-dependent across the dose range of
0.4–1.2 U/kg [68]. Due to an increase in the
risk of hypoglycemia with twice-daily dosing, a
once-daily schedule appears to provide the best
balance between efficacy and hypoglycemic risk
[65].
The receptor binding of insulin lispro is
unaffected by the protamine molecule and
ILPS therefore has the same binding profile as
insulin lispro. On this basis, the mitogenic and
immunogenic potentials of ILPS are expected to
be the same as those of insulin lispro.
Clinical Trials
Since data from pregnant women with diabetes
are limited, this section provides an overview of
clinical studies conducted in non-pregnant
women with pregestational diabetes or GDM.
In a prospective observational study in 64
patients with T1D or T2D whose diabetes was
inadequately controlled with oral antidiabetes
medications or other insulin regimens, ILPS
improved glycemic control without
significantly increasing hypoglycemic episodes
when used as basal insulin in intensive insulin
therapy [71]. Importantly, ILPS, as part of a
self-prepared combination with insulin lispro,
was not associated with a significant change in
binding levels to antibodies cross-reactive to
different insulin species (-0.1% with ILPS plus
insulin lispro versus -0.3% with regular human
insulin plus NPH insulin; no significant
difference between treatments) in a
randomized, open-label trial conducted in
patients with T1D or T2D [72].
ILPS once or twice daily has been compared
with other LAIAs in non-pregnant women with
diabetes in randomized trials of 24 to 36 weeks
duration (Table 2). Overall, ILPS achieved
similar glycemic control to insulin detemir
and insulin glargine, without increasing the
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risk of hypoglycemic episodes (overall or
nocturnal) or weight gain when used as
once-daily basal supplementation in patients
with T2D receiving oral antidiabetes
medications (Table 2) [74–78]. In one of these
studies, ILPS was administered with prandial
insulin lispro as part of a basal–bolus regimen
and compared with a basal–bolus regimen of
insulin glargine plus insulin lispro [77].
Glycemic control (change in HbA1c) and the
risk of hypoglycemia were similar with both
regimens.
Notably, the glycemic control achieved with
ILPS was often maintained with lower total
daily insulin doses than those required with
insulin detemir or insulin glargine in patients
with T1D [73] or T2D [74, 75]. In some studies,
when administered twice daily, ILPS appeared
to be associated with increased risk of nocturnal
hypoglycemia (Table 2) [73, 76, 78].
These data were confirmed in a meta-analysis
[79] and support the usefulness of ILPS as an
insulin analog for basal coverage in
non-pregnant patients with T1D or T2D.
Furthermore, the findings suggest that the
optimal regimen, in terms of balance between
efficacy and hypoglycemic risk, is a once-daily
injection [79], especially in patients with T2D
[65].
ILPS in Pregnancy
Insulin lispro does not cross the placental
barrier and is considered a useful treatment
option for pregnant women with diabetes [34].
As discussed in the Pharmacology section, ILPS
has the same binding properties as insulin
lispro, and also has a stable and
predictable pharmacological profile. Available
data concerning use of ILPS in pregnant women
are currently derived from retrospective
analyses conducted in Italian centers.
A retrospective cohort study of 89 pregnant
women with T2D or GDM showed that basal
therapy with either ILPS (N = 53) or NPH
insulin (N = 36), in addition to RAIAs (insulin
aspart or insulin lispro) in most patients,
resulted in similar maternal and pregnancy
outcomes, including glycemic control,
hypertension rates, and number of
hypoglycemic events. However, NPH insulin
resulted in a greater prevalence of
high-ponderal-index infants (three versus zero
infants with index[2.85 g/cm3; all three were
also receiving a RAIA) and in higher total
insulin doses than ILPS. Both insulins
appeared safe in this population [80].
A larger retrospective study evaluated data
from 612 pregnant women with T1D, T2D, or
GDM treated with ILPS insulin and data from a
control group of 793 similar women treated
with NPH insulin [81]. HbA1c improved during
pregnancy in both prepregnancy diabetes
groups (Table 3). Although no statistical results
were presented, there were fewer severe
hypoglycemic events and ketoacidosis events
reported in ILPS-treated women with T1D than
NPH insulin-treated women with T1D. In
women with T1D or T2D, the frequency of
cesarean section was lower with ILPS than with
NPH insulin (Table 3) [81]. In patients with
GDM, maternal and fetal outcomes were not
different in the two treatment groups (mean
maternal HbA1c values were not reported).
Thus, these data also suggest that ILPS is safe
and effective for use in pregnancy.
A separate and more recent Italian
multicenter observational retrospective study
evaluated pregnancy outcomes in another 119
women with T1D and 814 women with GDM
treated during pregnancy with ILPS or NPH
insulin [82]. Among patients with T1D, HbA1c
did not differ significantly between the two
treatment groups either before the pregnancy or
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during each trimester; however, third trimester
mean fasting blood glucose levels were
significantly lower in ILPS-treated women
(Table 4). Rates of severe hypoglycemic
episodes during pregnancy and insulin
requirements at the end of pregnancy were
Table 4 Pregnancy outcome and fetal parameters relating to women with T1D and GDM treated with ILPS or NPH











Weight gain during pregnancy, kg 11.9 (4.6) 13.2 (9.4) ns 10.2 (6.1) 9.7 (4.6) ns
HbA1c preconceptiona/at
diagnosis,b mmol/mol
61.7 (11.9) 57.4 (13) ns 36.6 (4.2) 35.5 (3.1) 0.04
HbA1c ﬁrst trimester, mmol/mol 56.3 (11.9) 56.3 (11.9) ns – – –
HbA1c second trimester, mmol/mol 48.6 (7.5) 47.5 (7.5) ns – – –
HbA1c third trimester, mmol/mol 49.7 (6.4) 47.5 (8.6) ns 36.3 (6.4) 35.6 (4.2) ns
Fasting glucose third trimester, mmol/l 6.0 (1.4) 7.7 (2.2) 0.001 4.9 (0.7) 6.3 (1.5) \0.001
Severe hypoglycemic episodes, % 5.2 13.1 ns 0.3 2.1 ns
Ketoacidosis episodes, % 0 0 – 0 0.4 ns
Basal insulin need at term
of pregnancy, U/kg
0.40 (0.20) 0.33 (0.14) ns 0.12 (0.09) 0.11 (0.07) ns
Delivery, gestational week 37.4 (2.4) 36.9 (2.2) ns 38.4 (1.9) 37.8 (1.7) 0.001
Cesarean section, % 48.2 63.9 0.001 31.2 46.2 0.01
Preterm delivery
(\37 gestational weeks), %
15.5 32.8 0.05 8.6 14.9 0.01
Stillbirths, % 3.4 1.6 ns 0.5 0.4 ns
Birth weight, g 3372 (788) 3304 (745) ns 3304 (505) 3286 (567) ns
Ponderal index, g/cm3 2.75 (0.4) 2.87 (0.5) ns 2.72 (0.3) 2.78 (0.6) ns
Ponderal index C2.85 g/cm3, % 29.3 42.6 ns 18.2 26.4 0.01
Macrosomia ([4000 g), % 18.9 16.3 ns 6.1 5.3 0.01
Small for gestational age, % 5.2 0 ns 3.1 5.4 ns
Large for gestational age, % 43.1 37.7 ns 16.6 19.4 ns
Congenital malformations, % 6.9 6.5 ns 0.5 1.6 ns
Neonatal hypoglycemia, % 8.6 4.9 ns 2.3 4.1 0.01
Data are presented as mean (standard deviation), unless stated otherwise
GDM gestational diabetes, HbA1c glycated hemoglobin, ILPS insulin lispro protamine suspension, NPH neutral protamine
Hagedorn, ns not signiﬁcant, T1D type 1 diabetes
a In patients with T1D
b In patients with GDM
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similar between treatment groups and no
patient had a ketoacidosis episode. As regards
pregnancy outcomes, rates of cesarean section
and preterm delivery were significantly lower in
women treated with ILPS than in those treated
with NPH insulin, although the mean duration
of pregnancy did not differ between treatment
groups. Fetal outcomes, including rates of
congenital malformation, were also similar in
the ILPS and NPH groups, with the exception
that a slightly higher proportion of newborns in
the NPH group had a ponderal index C2.85 g/
cm3 (not significant; Table 4).
Among women with GDM, third trimester
HbA1c did not differ significantly between
treatment groups, but fasting blood glucose
was lower in ILPS-treated women (Table 4).
There were no significant between-treatment
differences in the rates of severe hypoglycemic
or ketoacidotic episodes, or in insulin
requirements at the end of the pregnancy.
Pregnancy outcomes were generally better in
ILPS- than NPH-treated women, with the
duration of the pregnancy being significantly
longer, and the cesarean section and preterm
delivery rates lower in the ILPS-treated group.
When fetal outcomes were considered, ILPS was
associated with a significantly higher incidence
of macrosomia, and significantly fewer episodes
of neonatal hypoglycemia and newborns with
ponderal index C2.85 g/cm3 (Table 4). This
higher rate of macrosomia in the ILPS group
was possibly a result of the longer duration of
pregnancy, because the incidence of neonates
with a high ponderal index was lower in this
group than the NPH group, ruling out
dysmorphic growth as an etiological factor.
Bivariate logistic regression analysis of birth
weight and neonatal complications, including
congenital malformations and events associated
with perinatal complications, revealed no
statistically significant differences between
ILPS and NPH treatment. This large study
therefore confirms that use of ILPS in
conjunction with rapid-acting analogs in
pregnant patients with T1D or GDM is safe in
terms of maternal and fetal outcomes, and this
regimen achieves good metabolic control while
limiting fetal overgrowth [82].
CONCLUSION
Maternal metabolism changes during
pregnancy, posing numerous challenges in the
management of women with diabetes. As
insulin is the agent of choice for glycemic
control in these patients, selecting the most
appropriate insulin formulation is important.
Although a number of insulins are available for
use during pregnancy, insulin analogs are
particularly interesting for this use, as they
appear to reduce the risk of hypoglycemia and
promote a more physiological glycemic profile
than regular human insulin in pregnant women
with T1D, T2D, or GDM. The RAIAs, insulin
lispro and insulin aspart, and LAIAs, insulin
glargine and insulin detemir, can all be used in
pregnancy and are considered safe in terms of
maternal and fetal health. ILPS, an
intermediate- to long-acting insulin, is a
stable formulation of co-crystalized insulin
lispro and protamine that is expected to have
the same mitogenic and immunogenic
potentials as insulin lispro. Clinical data
support the usefulness of ILPS as a basal
insulin in non-pregnant patients with T1D or
T2D, and suggest the optimal regimen, in terms
of balance between efficacy and hypoglycemic
risk, is a once-daily injection, especially in
patients with T2D.
Most information regarding the use of
insulins in pregnant women with diabetes is
based on the results of observational studies; the
sample sizes of all RCTs comparing different
900 Adv Ther (2015) 32:888–905
insulin formulations in pregnant women have
not been adequate to allow sufficient power to
detect differences in neonatal outcomes. Data
concerning use of ILPS during pregnancy are no
exception to this, although findings from more
than 1200 pregnant women with T1D, T2D, or
GDM receiving this insulin are available and
have been compared with outcomes in
pregnant women receiving NPH insulin [81,
82]. Results of these retrospective studies
suggest that ILPS is at least as safe and
effective as NPH insulin in pregnant women.
Therefore, until adequate RCTs are
performed to provide more definitive findings,
available experimental and clinical information
indicates that ILPS has a stable and
predictable pharmacological profile and
appears to be a safe and effective option for
pregnant women with diabetes.
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